FDA to Require Supply of Mail-back Envelopes for Outpatient-dispensed Opioids

Examination of In-home Disposal Products also Planned; Notes on New DEA Registration Requirements On April 3, 2023, the U.S. Food and Drug Administration announced it is requiring manufacturers of opioid analgesics dispensed in outpatient settings (which includes home hospice care) to make prepaid mail-back envelopes available to outpatient pharmacies and other dispensers as an additional…